NCT06055010 (IMPACT) is a clinical trial of No interventions in Pancreatic Cancer, sponsored by UMC Utrecht.

Who is sponsoring NCT06055010?

NCT06055010 is sponsored by UMC Utrecht.

What drugs are being tested in NCT06055010?

Interventions in NCT06055010: No interventions.

What condition does NCT06055010 study?

NCT06055010 studies Pancreatic Cancer, Pancreatic Cyst, Pancreatic Adenocarcinoma, Pancreatic Diseases, Pancreas Adenocarcinoma, Pancreas Cyst.

Is NCT06055010 still recruiting?

NCT06055010 is currently recruiting now. Last updated 26 September 2023.

Last reviewed 2023-09-26 · How we verify

NCT06055010: IMPACT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Improving Pancreatic Cancer Care by the Use of Computational Science and Technology

Recruiting now Last updated 26 September 2023

What this trial tests

trial testing No interventions in Pancreatic Cancer in 5,000 participants. Currently enrolling.

Timeline

1 January 2014

Primary endpoint
31 December 2029

31 December 2029

Quick facts

Lead sponsor	UMC Utrecht
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	5,000
Start date	1 January 2014
Primary completion	31 December 2029
Estimated completion	31 December 2029
Sites	1 location across Netherlands

Drugs / interventions tested

No interventions — full drug profile →

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →
Pancreatic Cyst — all drugs for Pancreatic Cyst →
Pancreatic Adenocarcinoma — all drugs for Pancreatic Adenocarcinoma →
Pancreatic Diseases — all drugs for Pancreatic Diseases →

Sponsor

UMC Utrecht — full company profile →

Who can join

Eligibility, any sex, with Pancreatic Cancer or Pancreatic Cyst. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of the IMPACT project is to set up a data sharing infrastructure between expert centers for pancreatic surgery that enables training, testing and validation of computer science tools to improve quality of care for patients with pancreatic cancer.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Prediction of Isolated Local Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Study.
van Goor IWJM, Andel PCM, Buijs FS, Besselink MG, et al · · 2024 · cited 1× · PMID 38937412 · DOI 10.1245/s10434-024-15664-4
MKNet-family architectures for auto-segmentation of the residual pancreas after pancreatic resection: a deep learning comparative study.
Böhm D, Andel PCM, Akkermans PA, Boekestijn B, et al · · 2025 · PMID 41307673 · DOI 10.1007/s00261-025-05211-4
Pancreatic Ductal Adenocarcinoma (PDAC): A Review of Recent Advancements Enabled by Artificial Intelligence
Mukund A, Afridi M, Karolak A, Park M, et al · · 2024

Verify or expand the search:

Other trials of No interventions

Trials testing the same drug.

NCT07497815 — Artificial Intelligence-assisted Diagnosis in Ophthalmology · not yet recruiting
NCT07509632 — Predicting Pathological Complete Response in Rectal Cancer Using Machine Learning · active not recruiting
NCT07307040 — Precision Diabetes Management: Integrated East-West Approach · not yet recruiting
NCT07276945 — Individualized Early Diagnosis and Treatment System of Gestational Diabetes Mellitus (GDM) Based on New Continuous Gluco · not yet recruiting
NCT06999681 — Postoperative Arrhythmia and Preoperative Cardiac Function · not yet recruiting

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other UMC Utrecht trials

Trials by the same sponsor.

NCT07512336 — A Randomized Intra-Patient Controlled Trial of MagnetOs™ Putty vs Autograft in Instrumented Posterolateral Spinal Fusion · NA · not yet recruiting
NCT07485985 — Coronary Sinus Reducer Therapy for Persisting Angina · NA · not yet recruiting
NCT07449052 — Comprehensive Invasive Physiological Evaluation of Obstructive Coronary Artery Disease · NA · not yet recruiting
NCT05375708 — Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Me · Phase 2 · suspended
NCT06898541 — Coronary Sinus Reducer in Coronary Microvascular Disease · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06055010 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by UMC Utrecht
Last refreshed: 26 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06055010.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing